Health Minister Tyler Shandro announced Alberta is working with Novartis Pharmaceuticals Canada Inc. to provide interim access to Zolgensma for children suffering from spinal muscular atrophy (SMA) — a rare and progressive genetic disorder that causes muscle wasting. Kim Smith has more on Global News at Noon Edmonton.
Global News at Noon Edmonton
Alberta children with spinal muscular atrophy eligible for interim access to Zolgensma
More Videos
-
Study finds brawn does not mean brains when it comes to the T.Rex
-
It’s opening day for the $34B Trans Mountain oil pipeline expansion
-
Alberta Municipalities ‘caught off guard’ by details of Bill 20
-
Mitigating fire risk in Edmonton
-
Edmonton special Olympic athlete chosen in local advertising campaign
-
Education minister highlights changes in new draft of social studies curriculum
You are viewing an Accelerated Mobile Webpage.
View Original Article